Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

LYNN — After sweeping across more than 400 acres over the weekend, the wildfire is still here, smoldering in the ground ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

FOSTER CITY, Calif., November 08, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences ...